Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
HOME > INTERVIEW
INTERVIEW
-
Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
February 8, 2017
-
MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate
January 16, 2017
-
Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
December 2, 2016
-
Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research
August 18, 2016
-
Japan Biosimilar Association Aims to Share Knowledge and Experience to Popularize the Use of Biosimilars: Director General
August 5, 2016
-
Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
March 30, 2016
-
Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
March 23, 2015
-
EFPIA Japan Chairman Says Drug Costs Won’t Explode
January 14, 2015
-
Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.
November 28, 2014
ページ
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…